Long-term pharmacotherapy for obesity
- PMID: 15687412
- DOI: 10.1038/oby.2004.283
Long-term pharmacotherapy for obesity
Abstract
Obese patients unable to achieve significant weight loss with lifestyle changes alone may require drug therapy, and such therapy may be needed long term lest weight lost be regained. In the United States, only sibutramine and orlistat are available for the long-term treatment of obesity. Clinical trials have shown that both drugs can induce and maintain weight loss, even in patients with comorbid conditions such as hypertension or type 2 diabetes. Their use must be combined with behavior modification and a structured meal plan, however, for patients to reap the full benefits of such treatment.
Similar articles
-
The new role of pharmacotherapy for weight reduction in obesity.Int J Clin Pract. 2002 Nov;56(9):683-6. Int J Clin Pract. 2002. PMID: 12469983 Review.
-
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Diabetes Metab. 2002. PMID: 12522323 Review.
-
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.Obes Res. 2000 Sep;8(6):431-7. doi: 10.1038/oby.2000.53. Obes Res. 2000. PMID: 11011909 Clinical Trial.
-
Combining behavioral and pharmacological treatments for obesity.Obes Res. 2002 Jun;10(6):560-74. doi: 10.1038/oby.2002.77. Obes Res. 2002. PMID: 12055334 Review.
-
[Pharmacotherapy for weight loss in patients with type 2 diabetes].Ugeskr Laeger. 2007 Aug 13;169(33):2619-22. Ugeskr Laeger. 2007. PMID: 17725907 Danish. No abstract available.
Cited by
-
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.Am J Ther. 2009 Jul-Aug;16(4):354-64. doi: 10.1097/MJT.0b013e31817fde95. Am J Ther. 2009. PMID: 19092640 Free PMC article. Review.
-
Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment.Nutr Clin Pract. 2009 Dec;24(6):675-87. doi: 10.1177/0884533609351532. Nutr Clin Pract. 2009. PMID: 19955545 Free PMC article. Review.
-
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.Diabetes Metab Syndr Obes. 2010 May 10;3:125-43. doi: 10.2147/dmsott.s7005. Diabetes Metab Syndr Obes. 2010. PMID: 21437083 Free PMC article.
-
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease.Endocr Rev. 2025 Jul 15;46(4):479-500. doi: 10.1210/endrev/bnaf006. Endocr Rev. 2025. PMID: 39951489 Free PMC article. Review.
-
Rationale for multiple risk intervention: the need to move from theory to practice.Vasc Health Risk Manag. 2007;3(6):985-97. Vasc Health Risk Manag. 2007. PMID: 18200817 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical